GeoVax Labs (NASDAQ: GOVX) has highlighted that its recent Phase 2 findings for GEO-CM04S1 aligns with Infectious Diseases Society of America (IDSA) guidelines prioritizing vaccination for immunocompromised individuals.
According to GeoVax, the IDSA’s recommendations reinforce the company’s CEO-CM04S1 clinical data: robust T-cell responses, cross-variant durability, and favorable safety profile in vulnerable populations.
In a statement, David A. Dodd, chairman and CEO of GeoVax, commented, “Immunocompromised Americans are not a niche. They are cancer patients, transplant recipients, people with autoimmune disease, and those living with HIV—one in eight adults. They include family members, colleagues and neighbors. Yet mainstream vaccine approaches, heavily centered on mRNA, continue to leave them without durable protection. The new IDSA guidelines reinforce the urgent need for alternatives like GeoVax’s GEO-CM04S1.”
